BeiGene, Ltd. Stock

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-15 EDT 5-day change 1st Jan Change
138.4 USD -2.05% Intraday chart for BeiGene, Ltd. -7.58% -23.26%
Sales 2024 * 3.09B 4.26B Sales 2025 * 3.93B 5.41B Capitalization 14.76B 20.36B
Net income 2024 * -874M -1.21B Net income 2025 * -351M -484M EV / Sales 2024 * 4.27 x
Net cash position 2024 * 1.58B 2.17B Net cash position 2025 * 1.26B 1.74B EV / Sales 2025 * 3.44 x
P/E ratio 2024 *
-16.6 x
P/E ratio 2025 *
-44 x
Employees 10,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.05%
1 week-7.58%
Current month-11.50%
1 month-18.59%
3 months-20.12%
6 months-20.43%
Current year-23.26%
More quotes
1 week
137.38
Extreme 137.375
155.37
1 month
137.38
Extreme 137.375
171.25
Current year
132.95
Extreme 132.95
184.80
1 year
132.95
Extreme 132.95
270.57
3 years
118.18
Extreme 118.18
426.56
5 years
113.01
Extreme 113.01
426.56
10 years
22.51
Extreme 22.51
426.56
More quotes
Date Price Change Volume
24-04-15 138.4 -2.05% 228 153
24-04-12 141.3 -3.31% 139,454
24-04-11 146.1 -2.42% 243,171
24-04-10 149.8 -2.77% 272,924
24-04-09 154 +2.85% 115,201

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm

More quotes
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
141.3 USD
Average target price
268.6 USD
Spread / Average Target
+90.12%
Consensus